# Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

> **NCT07115446** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 63 (estimated)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** HS-20093
- **DRUG:** HRS-5041

## Key facts

- **NCT ID:** NCT07115446
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-19
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115446, "Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07115446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*